Alx Oncology Holdings Stock Today
| ALXO Stock | USD 0.75 0.02 2.60% |
PerformanceVery Weak
| Odds Of DistressLow
|
Alx Oncology is selling at 0.75 as of the 21st of March 2025; that is 2.6% down since the beginning of the trading day. The stock's open price was 0.77. Alx Oncology has about a 22 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of July 2020 | Category Healthcare | Classification Health Care |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company was founded in 2015 and is headquartered in South San Francisco, California. Alx Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 53.38 M outstanding shares of which 6.45 M shares are presently shorted by private and institutional investors with about 8.93 trading days to cover. More on Alx Oncology Holdings
Moving together with Alx Stock
Moving against Alx Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Alx Stock Highlights
| CEO Director | Jason Lettmann | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAlx Oncology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alx Oncology's financial leverage. It provides some insight into what part of Alx Oncology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alx Oncology Holdings (ALXO) is traded on NASDAQ Exchange in USA. It is located in 323 Allerton Avenue, South San Francisco, CA, United States, 94080 and employs 80 people. Alx Oncology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 39.96 M. Alx Oncology Holdings conducts business under Biotechnology sector and is part of Health Care industry. The entity has 53.38 M outstanding shares of which 6.45 M shares are presently shorted by private and institutional investors with about 8.93 trading days to cover.
Alx Oncology Holdings currently holds about 313.37 M in cash with (121.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Alx Oncology Probability Of Bankruptcy
Ownership AllocationAlx Oncology holds a total of 53.38 Million outstanding shares. The majority of Alx Oncology Holdings outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alx Oncology Holdings to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alx Oncology. Please pay attention to any change in the institutional holdings of Alx Oncology Holdings as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Alx Ownership Details
Alx Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bank Of Montreal | 2024-12-31 | 826.6 K | |
| Bmo Capital Markets Corp. | 2024-12-31 | 826.6 K | |
| Two Sigma Advisers, Llc | 2024-12-31 | 823.9 K | |
| Geode Capital Management, Llc | 2024-12-31 | 740.1 K | |
| Two Sigma Investments Llc | 2024-12-31 | 704.1 K | |
| State Street Corp | 2024-12-31 | 684.1 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 569 K | |
| Privium Fund Management B.v. | 2024-12-31 | 509.1 K | |
| Ubs Group Ag | 2024-12-31 | 408.1 K | |
| Venbio Partners Llc | 2024-12-31 | 9.7 M | |
| Redmile Group, Llc | 2024-12-31 | 3.7 M |
Alx Oncology Historical Income Statement
Alx Stock Against Markets
Alx Oncology Corporate Management
| Lisa Sauer | Senior Assurance | Profile | |
| Peter MBA | Chief Officer | Profile | |
| Christopher JD | General Counsel | Profile | |
| Shelly CPA | Interim Officer | Profile | |
| Corey Goodman | Independent Chairman | Profile | |
| Shelly Pinto | Senior Officer | Profile | |
| Caitlyn Doherty | Manager Communications | Profile |
Already Invested in Alx Oncology Holdings?
The danger of trading Alx Oncology Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alx Oncology is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alx Oncology. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alx Oncology Holdings is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alx Oncology Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alx Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alx Oncology Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alx Oncology Holdings Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.